These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10190291)

  • 21. Plasminogen activators and their inhibitors in leukemic cell homogenates.
    Wada H; Kumeda Y; Ogasawara Z; Ohiwa M; Kaneko T; Tamaki S; Ohno T; Kageyama S; Kobayashi T; Deguchi K
    Am J Hematol; 1993 Feb; 42(2):166-70. PubMed ID: 8438877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
    Buø L; Meling GI; Karlsrud TS; Johansen HT; Aasen AO
    Hum Pathol; 1995 Oct; 26(10):1133-8. PubMed ID: 7557947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
    Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
    Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system.
    Behrendt N; Danø K
    FEBS Lett; 1996 Sep; 393(1):31-6. PubMed ID: 8804418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Localization and significance of urokinase plasminogen activator and its receptor in placental tissue from intrauterine, ectopic and molar pregnancies.
    Floridon C; Nielsen O; Holund B; Sunde L; Westergaard JG; Thomsen SG; Teisner B
    Placenta; 1999 Nov; 20(8):711-21. PubMed ID: 10527826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferons and retinoids enhance and dexamethasone suppresses urokinase-mediated plasminogen activation in promyelocytic leukemia cells.
    Mustjoki S; Tapiovaara H; Sirén V; Vaheri A
    Leukemia; 1998 Feb; 12(2):164-74. PubMed ID: 9519778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines.
    Buø L; Bjørnland K; Karlsrud TS; Kvale D; Kjønniksen I; Fodstad O; Brandtzaeg P; Johansen HT; Aasen AO
    Anticancer Res; 1994; 14(6B):2445-51. PubMed ID: 7872665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator.
    Reinartz J; Schaefer B; Bechtel MJ; Kramer MD
    Exp Cell Res; 1996 Feb; 223(1):91-101. PubMed ID: 8635500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells.
    Hjertner O; Qvigstad G; Hjorth-Hansen H; Seidel C; Woodliff J; Epstein J; Waage A; Sundan A; Börset M
    Br J Haematol; 2000 Jun; 109(4):815-22. PubMed ID: 10929035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
    Biliran H; Sheng S
    Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S; Vrhovec I; Svetic B; Cufer T
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
    Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
    Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways.
    Schnaper HW; Barnathan ES; Mazar A; Maheshwari S; Ellis S; Cortez SL; Baricos WH; Kleinman HK
    J Cell Physiol; 1995 Oct; 165(1):107-18. PubMed ID: 7559792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy.
    Mustjoki S; Alitalo R; Stephens RW; Vaheri A
    Thromb Haemost; 1999 May; 81(5):705-10. PubMed ID: 10365741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
    Bauer TW; Fan F; Liu W; Johnson M; Parikh NU; Parry GC; Callahan J; Mazar AP; Gallick GE; Ellis LM
    Ann Surg; 2005 May; 241(5):748-56; discussion 756-8. PubMed ID: 15849510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface.
    Behrendt N; Rønne E; Danø K
    Biol Chem Hoppe Seyler; 1995 May; 376(5):269-79. PubMed ID: 7662169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.